biote (NASDAQ:BTMD – Get Free Report) and Guardant Health (NASDAQ:GH – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
Profitability
This table compares biote and Guardant Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| biote | -1.08% | -8.61% | 4.61% |
| Guardant Health | -37.93% | N/A | -25.03% |
Analyst Ratings
This is a summary of recent recommendations and price targets for biote and Guardant Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| biote | 1 | 1 | 1 | 1 | 2.50 |
| Guardant Health | 1 | 0 | 24 | 1 | 2.96 |
biote presently has a consensus target price of $2.50, suggesting a potential upside of 134.74%. Guardant Health has a consensus target price of $190.88, suggesting a potential upside of 25.83%. Given biote’s higher possible upside, research analysts clearly believe biote is more favorable than Guardant Health.
Earnings & Valuation
This table compares biote and Guardant Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| biote | $192.22 million | 0.20 | $27.05 million | ($0.10) | -10.65 |
| Guardant Health | $982.02 million | 20.90 | -$416.28 million | ($3.68) | -41.22 |
biote has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
21.7% of biote shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 5.6% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
biote has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500.
Summary
biote beats Guardant Health on 8 of the 14 factors compared between the two stocks.
About biote
Biote Inc. (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services. The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
